Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182579 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
A Phase 1 study, sponsored by Coordination Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06182579: Clinical Trial Phase 1 study, sponsored by Coordination Pharmaceuticals.
NCT06182579 is a Phase 1 study that was terminated before completion, run by Coordination Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182579, a Phase 1 study, was terminated before completion, sponsored by Coordination Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
Primary Outcome
The dose limiting toxicities of RiMO-401 with palliative radiation, as assessed by CTCAEv5, will not be observed in 33% or more patients
Interventions
- DRUG RiMO-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 1 |
Why NCT06182579 stopped before completion
NCT06182579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which RiMO-401 is the first listed.
NCT06182579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06182579 about?
NCT06182579 is a clinical study titled "Phase I Study of RiMO-401 With Radiation in Advanced Tumors". This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
What is the current status of trial NCT06182579?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-02-22. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06182579?
The interventions under investigation include: RiMO-401 (DRUG).
Who is sponsoring clinical trial NCT06182579?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06182579's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI